参考文献:(上下滑动可浏览)
[1] Centers for Disease Control and Prevention. (2015). Nearly half a million Americans suffered from clostridium difficile infections in a single year. https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html
[2] Singh, T., Bedi, P., Bumrah, K., Singh, J., Rai, M., & Seelam, S. (2019). Updates in Treatment of Recurrent Clostridium difficile Infection. Journal of Clinical Medicine Research, 11(7), 465–471.
[3] EISEMAN, B., SILEN, W., BASCOM, G. S., & KAUVAR, A. J. (1958). Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 44(5), 854–859.
[4] Schwan, A., Sjölin, S., Trottestam, U., & Aronsson, B. (1983).
Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet (London, England), 2(8354), 845.
[5] Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020). Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine, 29-30, 100642–100642.
[6] Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F., Tijssen, J. G., Speelman, P., Dijkgraaf, M. G., & Keller, J. J. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England journal of medicine, 368(5), 407–415.
[7] Mole, B. (2013). FDA gets to grips with faeces. Nature (London), 498(7453), 147–148.
[8] Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., Marion, J., Su, X., Braun, T., Bancke, L., & Feuerstadt, P. (2022). Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs, 82(15), 1527–1538.
[9] Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. ., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., Korman, L. Y., Ford, C. B., Litcofsky, K. D., Lombardo, M.-J., Wortman, J. R., Wu, H., Auniņš, J. G., McChalicher, C. W. ., Winkler, J. A., … von Moltke, L. (2022). SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. The New England Journal of Medicine, 386(3), 220–229.
[10] Finch. (2021). Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection. https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-announces-positive-topline-results-prism-ext/
[11] Vedanta Biosciences. (2021). Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA. https://www.vedantabio.com/news-media/press-releases/detail/2805/vedanta-announces-positive-topline-phase-2-data-for-ve303
[12] Guarner, F., & Malagelada, J. R. (2003). Gut flora in health and disease. Lancet (London, England), 361(9356), 512–519.
[13] Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P. L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., … Zitvogel, L. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, N.Y.), 342(6161), 971–976.
[14] Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., Dai, R.-M., Kiu, H., Cardone, M., Naik, S., Patri, A. K., Wang, E., Marincola, F. M., Frank, K. M., Belkaid, Y., … Goldszmid, R. S. (2013). Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment. Science (American Association for the Advancement of Science), 342(6161), 967–970.
[15] Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M.-L., Chang, E. B., & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science (American Association for the Advancement of Science), 350(6264), 1084–1089.
[16] Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., Poirier-Colame, V., Roux, A., Becharef, S., Formenti, S., Golden, E., Cording, S., Eberl, G., Schlitzer, A., Ginhoux, F., … Zitvogel, L. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (American Association for the Advancement of Science), 350(6264), 1079–1084.
[17] Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W., Hutchinson, D. S., Manzo, T., Petaccia De Macedo, M., Cotechini, T., Kumar, T., Chen, W. S., … Jiang, H. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (American Association for the Advancement of Science), 359(6371), 97–103.
[18] Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (American Association for the Advancement of Science), 359(6371), 104–108.
[19] Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., Ferrere, G., … Zitvogel, L. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, N.Y.), 359(6371), 91–97.
[20] Hayase, E., & Jenq, R. R. (2021). Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine, 13(1), 107–107.
[21] World Health Organization. (2022). Autism. https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders
[22] Autism Speaks. (2022). Autism statistics and facts. https://www.autismspeaks.org/autism-statistics-asd
[23] Buie, T., Campbell, D. B., Fuchs, G. J., 3rd, Furuta, G. T., Levy, J., Vandewater, J., Whitaker, A. H., Atkins, D., Bauman, M. L., Beaudet, A. L., Carr, E. G., Gershon, M. D., Hyman, S. L., Jirapinyo, P., Jyonouchi, H., Kooros, K., Kushak, R., Levitt, P., Levy, S. E., Lewis, J. D., … Winter, H. (2010). Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 125 Suppl 1, S1–S18.
[24] Hsiao, E. Y. E. Y., McBride, S. W. S. W., Hsien, S. S., Sharon, G. G., Hyde, E. R. E. R., McCue, T. T., Codelli, J. A. J. A., Chow, J. J., Reisman, S. E. S. E., Petrosino, J. F. J. F., Patterson, P. H. P. H., & Mazmanian, S. K. S. K. (2013). The microbiota modulates gut physiology and behavioral abnormalities associated with autism. Cell, 155(7), 1451–1463.
[25] Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., & Zhou, H. (2019). Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. Translational Psychiatry, 9(1), 43–43.
[26] Sharon, G., Cruz, N. J., Kang, D. W., Gandal, M. J., Wang, B., Kim, Y. M., Zink, E. M., Casey, C. P., Taylor, B. C., Lane, C. J., Bramer, L. M., Isern, N. G., Hoyt, D. W., Noecker, C., Sweredoski, M. J., Moradian, A., Borenstein, E., Jansson, J. K., Knight, R., Metz, T. O., … Mazmanian, S. K. (2019). Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell, 177(6), 1600–1618.e17.
[27] Kim, S., Kim, H., Yim, Y. S., Ha, S., Atarashi, K., Tan, T. G., Longman, R. S., Honda, K., Littman, D. R., Choi, G. B., & Huh, J. R. (2017). Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. Nature, 549(7673), 528–532.
[28] Garcia-Gutierrez, E., Narbad, A., & Rodríguez, J. M. (2020). Autism Spectrum Disorder Associated With Gut Microbiota at Immune, Metabolomic, and Neuroactive Level. Frontiers in Neuroscience, 14, 578666–578666.
[29] Yap, C. X., Henders, A. K., Alvares, G. A., Wood, D. L. A., Krause, L., Tyson, G. W., Restuadi, R., Wallace, L., McLaren, T., Hansell, N. K., Cleary, D., Grove, R., Hafekost, C., Harun, A., Holdsworth, H., Jellett, R., Khan, F., Lawson, L. P., Leslie, J., … Gratten, J. (2021). Autism-related dietary preferences mediate autism-gut microbiome associations. Cell, 184(24), 5916–5931.e17.
[30]Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., Pollard, E. L., Roux, S., Sadowsky, M. J., Lipson, K. S., Sullivan, M. B., Caporaso, J. G., & Krajmalnik-Brown, R. (2017). Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome, 5(1), 10–10.
[31] Heinlen, L., & Ballard, J. D. (2010). Clostridium difficile Infection. The American Journal of the Medical Sciences, 340(3), 247–252.
[32] DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. ., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019). Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. The New England Journal of Medicine, 381(21), 2043–2050.
[33] U.S. FOOD & DRUG ADMINISTRATION. (2020). Safety alert re: FMT and SARS-COV-2 and COVID-19. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections
[34] 中国营养学会益生菌益生元与健康分会,向雪松,陈潇.(2019). 共识解读 | 我国批准的益生菌菌种名单. 中国科协科学传播专家团队. https://zhuanjia.kpcswa.org.cn/article/view.php?aid=46
[35] Underwood, E. (2013, December 5). Gut microbes linked to autismlike symptoms in mice. Science. https://www.science.org/content/article/gut-microbes-linked-autismlike-symptoms-mice
[36] Troy, E. B., & Kasper, D. L. (2010). Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Frontiers in Bioscience, 15(1), 25–34.
[37] Lee, Y. K., Mehrabian, P., Boyajian, S., Wu, W.-L., Selicha, J., Vonderfecht, S., & Mazmanian, S. K. (2018). The Protective Role of Bacteroides fragilis in Murine Model of Colitis-Associated Colorectal Cancer. mSphere, 3(6).
[38] Klarity. (2022). Our Purpose-Built Therapeutic Platform: A Unique Combination of Technologies. https://kallyope.com/platform/
[39] Switzerland, B., & Finland, K. (2022, June 15). Aurealis Therapeutics successfully completes treatment period of its phase 1 study for AUP-16 in non-healing diabetic foot ulcers: 83% patients receiving lead therapeutic dose achieved complete healing. Aurealis Therapeutics. https://aurealistherapeutics.com/aup-16-phase-1-study-completed/
[40] Puurunen, M. K., Vockley, J., Searle, S. L., Sacharow, S. J., Phillips, J. A., 3rd, Denney, W. S., Goodlett, B. D., Wagner, D. A., Blankstein, L., Castillo, M. J., Charbonneau, M. R., Isabella, V. M., Sethuraman, V. V., Riese, R. J., Kurtz, C. B., & Brennan, A. M. (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature metabolism, 3(8), 1125–1132.
[41] Puurunen, M. K., Vockley, J., Searle, S. L., Sacharow, S. J., Phillips, J. A., 3rd, Denney, W. S., Goodlett, B. D., Wagner, D. A., Blankstein, L., Castillo, M. J., Charbonneau, M. R., Isabella, V. M., Sethuraman, V. V., Riese, R. J., Kurtz, C. B., & Brennan, A. M. (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature metabolism, 3(8), 1125–1132.